Eisai, Solstice Ink European Copromotion Deal For Botox Competitor
This article was originally published in The Pink Sheet Daily
Firms also plan to seek several non-cosmetic indications for the biologic, for which clinical trials have shown some advantages over Allergan’s Botox, Solstice CEO tells “The Pink Sheet” DAILY.
You may also be interested in...
FDA clears Botox for the treatment of primary axillary hyperhidrosis that is inadequately managed with topical agents. An FDA Talk Paper states patients should be evaluated for other potential causes of the problem, such as hyperthyroidism, prior to treatment.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee
Agency comes to same conclusion as advisory committee: the risky schizophrenia drug could get approved if an appropriate patient group is identified.